Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Company to present at the 44th Annual JP Morgan Healthcare ConferenceFREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% co ...